Alberta BioEvolution Poster: Now available...

Alberta BioEvolution is a one-of-a-kind genealogy chart that illustrates the founding "technology origins" of more than 40 biotechnology and medical device firms located in the province of Alberta.

Destination Alberta

This section will answer many of your questions regarding the life science industry in Alberta, the province's economy, tax structure and cost of living, education, transportation, climate, recreational opportunities, history, industry resources, and more.

Local News...

Free News Release Posting & Archiving Service


• Cardiac Science initiates voluntary field corrective action of certain AEDs  Cardiac Science that it has initiated a worldwide voluntary field corrective action of certain automated external defibrillators (AEDs) manufactured between August 2006 and March 2007.
  Cardiac Science Corporation  October 13, 2008  
  
  
• GE Healthcare and Boston Scientific collaborate on cardiovascular imaging  GE Healthcare and intravascular ultrasound market leader Boston Scientific announced a collaboration that enables improved intravascular ultrasound workflow between the GE Healthcare Innova(R) Cardiovascular X-ray System and the Boston Scientific iLab(R) Ultrasound Imaging System.
  Boston Scientific Corporation  October 13, 2008  
  
  
• Abbott announces new $5 billion share repurchase program  Abbott's board of directors has authorized the repurchase of up to $5 billion of the corporation's common stock. The purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.
  Abbott  October 13, 2008  
  
  
• New data shows Abbott's bioabsorbable drug eluting stent is absorbed within two years  Abbott announced trial data demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries.
  Abbott  October 13, 2008  
  
  
• OncoGenex achieves key regulatory milestone for lead product candidate, OGX-011  OncoGenex announced that it concluded a meeting with the FDA on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
  OncoGenex Pharmaceuticals Inc.  October 13, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Quality Control Chemist I Bio-Rad Laboratories, Inc. (WA)
• Neuroscience Research Manager Swedish Medical Center (WA)
• Vice President, Business Development OncoGenex Technologies Inc. (BC)
• Research Associate, Formulation/Process Development Infectious Disease Research Institute (IDRI) (WA)
• Project Manager Pacific Biometrics, Inc. (WA)

More... | Job Advertising... | About Job Postings...

New Facilities Available...

ATC clean room constructors...validation guaranteed!

• Epigenomics Lab/Office Space -- Seattle, WA
• Icogenex Biotech Incubator -- Seattle, WA
• SIRTI Technology Center -- Spokane, WA
• University of Iowa Oakdale Research Park Biotech Building -- Coralville, IA
• University of Iowa Oakdale Research Park BioVentures Center -- Coralville, IA

More... | Facility Advertising...

Upcoming Events...

Free Event Posting Service

• 10/14/2008: Innovation in Life Science & Healthcare Research and Product Development
• 10/14/2008: Preparing for a FDA Audit
• 10/14/2008: GAMP Validation Protocols for Efficient Documentation
• 10/14/2008: Applying Human Factors Best Practices for Medical Device Risk Management
• 10/14/2008: Montana Geriatric Education Conference

More... | Submit Event | Event Advertising...